Header Logo

Connection

Michael Liptay to Prognosis

Back to Details
This is a "connection" page, showing publications Michael Liptay has written about Prognosis.
Michael Liptay
Connection Strength
0.706
Prognosis
  1. Diffusion lung capacity for carbon monoxide (DLCO) is an independent prognostic factor for long-term survival after curative lung resection for cancer. J Surg Oncol. 2009 Dec 15; 100(8):703-7.
    View in: PubMed
    Score: 0.074
  2. Pneumonectomy after chemoradiation therapy for non-small cell lung cancer: does "side" really matter? Ann Thorac Surg. 2009 Sep; 88(3):937-43; discussion 944.
    View in: PubMed
    Score: 0.073
  3. Intraoperative sentinel node mapping with technitium-99 in lung cancer: results of CALGB 140203 multicenter phase II trial. J Thorac Oncol. 2009 Feb; 4(2):198-202.
    View in: PubMed
    Score: 0.070
  4. Sentinel node mapping in lung cancer: introduction. Semin Thorac Cardiovasc Surg. 2009; 21(4):297.
    View in: PubMed
    Score: 0.069
  5. Repeat pulmonary resection for metachronous colorectal carcinoma is beneficial. Surgery. 2008 Oct; 144(4):712-7; discussion 717-8.
    View in: PubMed
    Score: 0.068
  6. Sentinel node mapping in lung cancer: the Holy Grail? Ann Thorac Surg. 2008 Feb; 85(2):S778-9.
    View in: PubMed
    Score: 0.065
  7. The role of IGF-pathway biomarkers in determining risks, screening, and prognosis in lung cancer. Oncotarget. 2022; 13:393-407.
    View in: PubMed
    Score: 0.043
  8. Intraoperative radioisotope sentinel lymph node mapping in non-small cell lung cancer. Ann Thorac Surg. 2000 Aug; 70(2):384-9; discussion 389-90.
    View in: PubMed
    Score: 0.039
  9. Solitary pulmonary nodule: treatment options. Chest. 1999 Dec; 116(6 Suppl):517S-518S.
    View in: PubMed
    Score: 0.037
  10. Serum Biomarkers May Prognosticate Recurrence in Node-Negative, Non-Small Cell Lung Cancers Less Than 4 Centimeters. Ann Thorac Surg. 2017 Nov; 104(5):1637-1643.
    View in: PubMed
    Score: 0.032
  11. Circulating angiogenesis biomarkers are associated with disease progression in lung adenocarcinoma. Ann Thorac Surg. 2014 Dec; 98(6):1968-75; discussion 1975.
    View in: PubMed
    Score: 0.026
  12. Prognostic significance of weight gain during definitive chemoradiotherapy for locally advanced non-small-cell lung cancer. Clin Lung Cancer. 2013 Jul; 14(4):370-5.
    View in: PubMed
    Score: 0.023
  13. CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients. Diagn Mol Pathol. 2012 Dec; 21(4):207-13.
    View in: PubMed
    Score: 0.023
  14. STS database risk models: predictors of mortality and major morbidity for lung cancer resection. Ann Thorac Surg. 2010 Sep; 90(3):875-81; discussion 881-3.
    View in: PubMed
    Score: 0.019
  15. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int J Cancer. 2010 Apr 01; 126(7):1630-9.
    View in: PubMed
    Score: 0.019
  16. A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer. Lung Cancer. 2004 Aug; 45(2):243-53.
    View in: PubMed
    Score: 0.013
  17. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. Ann Surg. 1996 Sep; 224(3):288-94; discussion 294-6.
    View in: PubMed
    Score: 0.007
  18. An historical perspective of multi-modality treatment for resectable non-small cell lung cancer. Lung Cancer. 1995 Jun; 12 Suppl 2:S17-32.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.